Aardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00 at Bank of America

Aardvark Therapeutics (NASDAQ:AARD) had its target price increased by analysts at Bank of America from $22.00 to $26.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective indicates a potential upside of 151.45% from the company’s previous close.

A number of other analysts have also recently issued reports on AARD. Cantor Fitzgerald started coverage on Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $50.00 price objective for the company. Royal Bank of Canada started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They set an “overweight” rating and a $29.00 target price for the company.

Aardvark Therapeutics Stock Up 9.8 %

Shares of AARD stock traded up $0.92 on Thursday, reaching $10.34. The stock had a trading volume of 5,396 shares, compared to its average volume of 130,950. Aardvark Therapeutics has a 12 month low of $8.60 and a 12 month high of $19.58.

Insider Buying and Selling

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 16,542 shares of the business’s stock in a transaction on Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Nelson Sun bought 10,000 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the acquisition, the chief financial officer now owns 99,484 shares in the company, valued at approximately $1,591,744. This represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.